Poster Session II - A192 DUPILUMAB IMPROVES FEATURES OF EOSINOPHILIC ESOPHAGITIS REGARDLESS OF ENDOSCOPIC PHENOTYPE: LIBERTY EOE TREET STUDY POST HOC ANALYSIS

Abstract Background In LIBERTY EoE TREET (NCT03633617), dupilumab improved histologic, symptomatic, and endoscopic EoE features up to 52 weeks. Aims To assess the effect of dupilumab in adolescents and adults with EoE by baseline endoscopic profile. Methods Patients (pts) with EoE aged ≥12 years received either 24 weeks of dupilumab 300 mg weekly or placebo (PBO). Eligible pts who completed 24 weeks of treatment received dupilumab to Week (W)52. Pts were categorized by baseline endoscopic profile (inflammatory or mixed). Pts achieving peak eosinophil count (PEC) ≤6 eosinophils per high-power field (eos/hpf) and change from baseline in Dysphagia Symptom Questionnaire (DSQ) score, Endoscopic Reference Score (EREFS) total score, inflammatory (edema, exudate, furrow) and fibrostenotic (ring, stricture) subscores were assessed at W24 and W52. All P-values are nominal. Results Of 240 pts, 32.9%/63.3% had an inflammatory/mixed baseline endoscopic profile. Pts with a mixed profile were older than those with an inflammatory profile (mean 33.8 years [standard deviation 12.4] vs 20.7 [10.9], P